FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1030-1037 April 18, 1996 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Invasive cervical cancer is uncommon in the United States, with an incidence of 15,800 cases and 4800 deaths in 1995.¹ This relatively low incidence is largely due to the effectiveness of screening programs that assess cervical cytology by Pap smear. On a global scale, however, cancer of the cervix is a major cause of death, especially in Third World countries, where such screening is often not routinely performed. Pap-smear screening is designed to detect precursor lesions in cervical epithelium, which may antedate the development of invasive cancer by several years. In contrast to other screening strategies, such as mammography, which . . . [Full Text of this Article]

Epidemiology and Risk Factors

Role of Human Papillomavirus in the Development of Cervical Cancer

Pap-Smear Screening

Interpretation of Pap Smears

Evaluation and Care of Patients with Abnormal Pap Smears

Management of Invasive Disease

Stage IA

Stages IB and IIA

Stages IIB, III, and IVA

Management of Recurrent Disease

Chemotherapy in Patients with Newly Diagnosed Disease

Summary and Future Directions

Source Information

From the Division of Medical Oncology, Department of Medicine, Dana–Farber Cancer Institute (S.A.C.); the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Beth Israel Hospital (J.M.N.); and Harvard Medical School (S.A.C., J.M.N.) — all in Boston.

Address reprint requests to Dr. Cannistra at the Dana–Farber Cancer Institute, 44 Binney St., Boston, MA 02115.

References

This article has been cited by other articles:

• Boulet, G. A.V., Horvath, C. A.J., Berghmans, S., Bogers, J. (2008). Human Papillomavirus in Cervical Cancer Screening: Important Role as Biomarker. Cancer Epidemiol. Biomarkers Prev. 17: 810-817 [Abstract] [Full Text]  
• Ju, X.-Z., Yang, J.-M., Zhou, X.-Y., Li, Z.-T., Wu, X.-H. (2008). EMMPRIN Expression as a Prognostic Factor in Radiotherapy of Cervical Cancer. Clin. Cancer Res. 14: 494-501 [Abstract] [Full Text]  
• van Luijk, I., Coens, C, van der Burg, M., Kobierska, A, Namer, M, Lhomme, C, Zola, P, Zanetta, G, Vermorken, J., For the Gynecological Cancer Group of the European, (2007). Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix. Ann Oncol 18: 275-281 [Abstract] [Full Text]  
• Smith, K. L., Tristram, A., Gallagher, K. M., Fiander, A. N., Man, S. (2005). Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. Int Immunol 17: 167-176 [Abstract] [Full Text]  
• Mandic, A., Vujkov, T. (2004). Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future?. Ann Oncol 15: 197-200 [Abstract] [Full Text]  
• Adab, P, Marshall, T, Rouse, A, Randhawa, B, Sangha, H, Bhangoo, N (2003). Randomised controlled trial of the effect of evidence based information on women's willingness to participate in cervical cancer screening. J. Epidemiol. Community Health 57: 589-593 [Abstract] [Full Text]  
• Jeong, Y. Y., Kang, H. K., Chung, T. W., Seo, J. J., Park, J. G. (2003). Uterine Cervical Carcinoma after Therapy: CT and MR Imaging Findings. RadioGraphics 23: 969-981 [Abstract] [Full Text]  
• Kelley, C. G., Daly, B. J., Anthony, M. K., Zauszniewski, J. A., Stange, K. C. (2002). Nurse Practitioners and Preventive Screening in the Hospital. Clin Nurs Res 11: 433-449 [Abstract]  
• Mansley, E. C., Dunet, D. O., May, D. S., Chattopadhyay, S. K., McKenna, M. T. (2002). Variation in Average Costs among Federally Sponsored State-Organized Cancer Detection Programs: Economies of Scale?. Med Decis Making 22: S67-S79 [Abstract]  
• Fiorica, J. V. (2002). Update on the Treatment of Cervical and Uterine Carcinoma: Focus on Topotecan. The Oncologist 7: 36-45 [Abstract] [Full Text]  
• Imoto, I., Tsuda, H., Hirasawa, A., Miura, M., Sakamoto, M., Hirohashi, S., Inazawa, J. (2002). Expression of cIAP1, a Target for 11q22 Amplification, Correlates with Resistance of Cervical Cancers to Radiotherapy. Cancer Res. 62: 4860-4866 [Abstract] [Full Text]  
• Klencke, B., Matijevic, M., Urban, R. G., Lathey, J. L., Hedley, M. L., Berry, M., Thatcher, J., Weinberg, V., Wilson, J., Darragh, T., Jay, N., Da Costa, M., Palefsky, J. M. (2002). Encapsulated Plasmid DNA Treatment for Human Papillomavirus 16-associated Anal Dysplasia: A Phase I Study of ZYC101. Clin. Cancer Res. 8: 1028-1037 [Abstract] [Full Text]  
• Levine, A. M. (2002). Evaluation and Management of HIV-Infected Women. ANN INTERN MED 136: 228-242 [Abstract] [Full Text]  
• Oh, S. T., Kyo, S., Laimins, L. A. (2001). Telomerase Activation by Human Papillomavirus Type 16 E6 Protein: Induction of Human Telomerase Reverse Transcriptase Expression through Myc and GC-Rich Sp1 Binding Sites. J. Virol. 75: 5559-5566 [Abstract] [Full Text]  
• De Hertog, S. A.E., Wensveen, C. A.H., Bastiaens, M. T., Kielich, C. J., Berkhout, M. J.P., Westendorp, R. G.J., Vermeer, B. J., Bouwes Bavinck, J. N. (2001). Relation Between Smoking and Skin Cancer. JCO 19: 231-238 [Abstract] [Full Text]  
• Taylor, L. A., Sorensen, S. V., Ray, N. F., Halpern, M. T., Harper, D. M. (2000). Cost-effectiveness of the Conventional Papanicolaou Test With a New Adjunct to Cytological Screening for Squamous Cell Carcinoma of the Uterine Cervix and Its Precursors. Arch Fam Med 9: 713-721 [Abstract] [Full Text]  
• Rozendaal, L, Westerga, J, van der Linden, J C, Walboomers, J M M, Voorhorst, F J, Risse, E K J, Boon, M E, Meijer, C J L M (2000). PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J. Clin. Pathol. 53: 606-611 [Abstract] [Full Text]  
• Lacey, J. V. Jr., Brinton, L. A., Abbas, F. M., Barnes, W. A., Gravitt, P. E., Greenberg, M. D., Greene, S. M., Hadjimichael, O. C., McGowan, L., Mortel, R., Schwartz, P. E., Silverberg, S. G., Hildesheim, A. (1999). Oral Contraceptives as Risk Factors for Cervical Adenocarcinomas and Squamous Cell Carcinomas. Cancer Epidemiol. Biomarkers Prev. 8: 1079-1085 [Abstract] [Full Text]  
• Fulcher, A. S., O'Sullivan, S. G., Segreti, E. M., Kavanagh, B. D. (1999). Recurrent Cervical Carcinoma: Typical and Atypical Manifestations. RadioGraphics 19: 103-116 [Abstract] [Full Text]  
• Rose, P. G., Blessing, J. A., Gershenson, D. M., McGehee, R. (1999). Paclitaxel and Cisplatin as First-Line Therapy in Recurrent or Advanced Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. JCO 17: 2676-2676 [Abstract] [Full Text]  
• Savard, J., Miller, S. M., Mills, M., O'Leary, A., Harding, H., Douglas, S. D., Mangan, C. E., Belch, R., Winokur, A. (1999). Association Between Subjective Sleep Quality and Depression on Immunocompetence in Low-Income Women at Risk for Cervical Cancer. Psychosom. Med. 61: 496-507 [Abstract] [Full Text]  
• Pignata, S., Silvestro, G., Ferrari, E., Selvaggi, L., Perrone, F., Maffeo, A., Frezza, P., Di Vagno, G., Casella, G., Ricchi, P., Cormio, G., Gallo, C., Iodice, F., Romeo, F., Fiorentino, R., Fortuna, G., Tramontana, S. (1999). Phase II Study of Cisplatin and Vinorelbine as First-Line Chemotherapy in Patients With Carcinoma of the Uterine Cervix. JCO 17: 756-756 [Abstract] [Full Text]  
• Sun, X.-L., Jayaram, H. N., Gharehbaghi, K., Li, Q.-J., Xiao, X., Antony, A. C. (1999). Modulation of the Cytotoxicity of 3'-Azido-3'-deoxythymidine and Methotrexate after Transduction of Folate Receptor cDNA into Human Cervical Carcinoma: Identification of a Correlation between Folate Receptor Expression and Thymidine Kinase Activity. Cancer Res. 59: 940-946 [Abstract] [Full Text]  
• Bjorge, T., Dillner, J., Anttila, T., Engeland, A., Hakulinen, T., Jellum, E., Lehtinen, M., Luostarinen, T., Paavonen, J., Pukkala, E., Sapp, M., Schiller, J., Youngman, L., Thoresen, S. (1997). Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ 315: 646-649 [Abstract] [Full Text]  
• Raffle, A E (1997). Informed participation in screening is essential. BMJ 314: 1762-1762 [Full Text]  
• Hubbell, F. A., Chavez, L. R., Mishra, S. I., Valdez, R. B. (1996). Beliefs About Sexual Behavior and Other Predictors of Papanicolaou Smear Screening Among Latinas and Anglo Women. Arch Intern Med 156: 2353-2358 [Abstract]